Comparative Pharmacology
Head-to-head clinical analysis: ACTAHIST versus HYDROXYZINE PAMOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTAHIST versus HYDROXYZINE PAMOATE.
ACTAHIST vs HYDROXYZINE PAMOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Hydroxyzine pamoate is a piperazine derivative with antihistamine (H1 receptor antagonist) and anticholinergic properties. It also has sedative, anxiolytic, and antiemetic effects, likely mediated through suppression of subcortical regions of the central nervous system.
1.34 mg (one capsule) orally twice daily.
Oral: 50-100 mg every 6 hours as needed for pruritus or anxiety; maximum 600 mg/day. IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Terminal elimination half-life is approximately 20 hours (range 14-25 hours) in adults; may be prolonged in elderly or hepatic impairment.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of metabolites.
Category C
Category A/B
Antihistamine
Antihistamine